InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: friendofthedevil post# 3533

Sunday, 10/05/2014 4:33:50 PM

Sunday, October 05, 2014 4:33:50 PM

Post# of 8557
No argument here. My point is, they have presentable data from the first year of the PAG study and that data was good enough for the Fast Track designation. When it is presented doesn't matter to me.

The Gem study was a 1B/2 trial, cut short after Abraxane was approved, in order to study Peg with most efficacious/low side effect approved treatment.

Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News